OKYO Pharma Starts Phase 2 Trial for OK-101
Ticker: OKYO · Form: 6-K · Filed: Oct 16, 2024 · CIK: 1849296
| Field | Detail |
|---|---|
| Company | Okyo Pharma LTD (OKYO) |
| Form Type | 6-K |
| Filed Date | Oct 16, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial, drug-development, biotech
TL;DR
OKYO Pharma just kicked off a Phase 2 trial for OK-101 to treat NCP, starting patient recruitment.
AI Summary
On October 16, 2024, OKYO Pharma Ltd announced the commencement of patient screening and recruitment for a Phase 2 clinical trial of its drug OK-101. This trial aims to treat Nasal and Conjunctival Congestion (NCP) and is designed as a 12-week, double-masked, randomized, placebo-controlled study.
Why It Matters
This marks a significant step in the development of OK-101, potentially leading to a new treatment option for patients suffering from NCP.
Risk Assessment
Risk Level: medium — Clinical trial initiations carry inherent risks related to trial success, regulatory approval, and market adoption.
Key Numbers
- Phase 2 — Clinical Trial Phase (The current stage of development for OK-101.)
- 12-week — Trial Duration (The planned length of the Phase 2 study.)
Key Players & Entities
- OKYO Pharma Ltd (company) — Registrant
- OK-101 (drug) — Investigational drug for NCP treatment
- NCP (medical_condition) — Condition OK-101 is intended to treat
- October 16, 2024 (date) — Date of announcement and trial commencement
FAQ
What is the primary objective of the Phase 2 trial for OK-101?
The primary objective is to evaluate OK-101 for the treatment of Nasal and Conjunctival Congestion (NCP).
When did OKYO Pharma Ltd announce the start of patient recruitment?
OKYO Pharma Ltd announced the start of patient screening and recruitment on October 16, 2024.
What is the design of the Phase 2 trial for OK-101?
The trial is designed as a double-masked, randomized, 12-week placebo-controlled study.
What condition is OK-101 intended to treat?
OK-101 is intended to treat Nasal and Conjunctival Congestion (NCP).
What is the filing type and date for this announcement?
This is a Form 6-K filing, dated October 16, 2024.
Filing Stats: 386 words · 2 min read · ~1 pages · Grade level 13.6 · Accepted 2024-10-16 07:00:07
Filing Documents
- form6-k.htm (6-K) — 26KB
- ex99-1.htm (EX-99.1) — 19KB
- ex99-1_001.jpg (GRAPHIC) — 20KB
- 0001493152-24-041229.txt ( ) — 74KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: October 16, 2024 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 Announcement, dated October 16, 2024 4